100 CAMPUS DRIVE, FLORHAM PARK, NJ
Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Stockholders Approve Amendment to 2021 Stock Incentive Plan
Director Departure - Stefan D. Loren Not Standing for Reelection
Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Cellectar Biosciences Enters Registered Direct Offering of 1,618,053 Shares
Financial Results, Press Release
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Earnings Release
Q2
Q1
Amended Annual Report
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload